Aliases & Classifications for Capillary Disease

MalaCards integrated aliases for Capillary Disease:

Name: Capillary Disease 12 14
Disease of Capillaries 12 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1271
ICD10 32 I78 I78.9
ICD9CM 34 448
UMLS 69 C0155765

Summaries for Capillary Disease

Disease Ontology : 12 A vascular disease that is located in the capillaries.

MalaCards based summary : Capillary Disease, also known as disease of capillaries, is related to burns and eosinophilic gastroenteritis, and has symptoms including petechiae of skin An important gene associated with Capillary Disease is IL2 (Interleukin 2), and among its related pathways/superpathways are Photodynamic therapy-induced NF-kB survival signaling and IL-15 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types. The drugs Bosentan and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include the capillaries, endothelial and bone.

Wikipedia : 72 A capillary (/ˈkæpɪlɛri/ in US; /kəˈpɪləri/ in UK) is a small blood vessel from 5 to 10 micrometres (µm)... more...

Related Diseases for Capillary Disease

Diseases related to Capillary Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Related Disease Score Top Affiliating Genes
1 burns 10.3 ALB CSF2
2 eosinophilic gastroenteritis 10.3 ALB CSF2
3 pure red-cell aplasia 10.3 ALB IL2
4 night blindness, congenital stationary, type 1a 10.3 ALB CSF2
5 hydrops, lactic acidosis, and sideroblastic anemia 10.2 ALB SERPING1
6 smallpox 10.2 CSF2 IL2
7 capillary leak syndrome 10.1 ALB CSF2 IL2
8 leukocyte disease 10.1 ALB CSF2 IL2
9 acquired immunodeficiency syndrome 10.1 ALB CSF2 IL2
10 immune system disease 10.1 ALB CSF2 IL2
11 filariasis 10.1 ALB IL2
12 mastitis 10.1 ALB CSF2
13 pulmonary sarcoidosis 10.1 CSF2 IL2
14 mucositis 10.0 CSF2 IL2
15 gastric lymphoma 9.9 ALB ATP12A
16 fungal esophagitis 9.9 ATP12A ATP4A
17 bladder calculus 9.9 ATP12A ATP4A
18 gastrointestinal neuroendocrine benign tumor 9.9 ATP12A ATP4A
19 gastric neuroendocrine neoplasm 9.9 ATP12A ATP4A
20 neonatal candidiasis 9.9 ATP12A ATP4A
21 photoallergic dermatitis 9.9 ATP12A ATP4A
22 squamous papillomatosis 9.9 ATP12A ATP4A
23 acute laryngitis 9.9 ATP12A ATP4A
24 hereditary hemorrhagic telangiectasia 9.9
25 gastroduodenal crohn's disease 9.9 ATP12A ATP4A
26 toxic megacolon 9.9 ATP12A ATP4A
27 aspiration pneumonitis 9.9 ATP12A ATP4A
28 gastric antral vascular ectasia 9.9 ATP12A ATP4A
29 esophageal candidiasis 9.9 ATP12A ATP4A
30 postsurgical hypothyroidism 9.9 ATP12A ATP4A
31 rumination disorder 9.9 ATP12A ATP4A
32 laryngeal disease 9.9 ATP12A ATP4A
33 duodenitis 9.9 ATP12A ATP4A
34 congenital disorder of deglycosylation 9.9 ATP12A ATP4A
35 bile reflux 9.9 ATP12A ATP4A
36 granulomatous gastritis 9.9 ATP12A ATP4A
37 active peptic ulcer disease 9.9 ATP12A ATP4A
38 dyskinesia of esophagus 9.9 ATP12A ATP4A
39 ischemic neuropathy 9.9 ATP12A ATP4A
40 anismus 9.9 ATP12A ATP4A
41 peptic esophagitis 9.9 ATP12A ATP4A
42 duodenal disease 9.9 ATP12A ATP4A
43 hernia, hiatus 9.9 ATP12A ATP4A
44 esophageal atresia/tracheoesophageal fistula 9.9 ATP12A ATP4A
45 laryngitis 9.9 ATP12A ATP4A
46 laryngeal tuberculosis 9.9 ATP12A ATP4A
47 lymphocytic colitis 9.9 ATP12A ATP4A
48 chronic intestinal vascular insufficiency 9.9 ATP12A ATP4A
49 clostridium difficile colitis 9.9 ATP12A ATP4A
50 lower urinary tract calculus 9.9 ATP12A ATP4A

Graphical network of the top 20 diseases related to Capillary Disease:



Diseases related to Capillary Disease

Symptoms & Phenotypes for Capillary Disease

UMLS symptoms related to Capillary Disease:


petechiae of skin

Drugs & Therapeutics for Capillary Disease

Drugs for Capillary Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 259)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bosentan Approved, Investigational Phase 4,Phase 2 147536-97-8 104865
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
3
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
4
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 53-03-2 5865
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
7
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3 26787-78-0 33613 2171
8
Clarithromycin Approved Phase 4,Phase 2,Phase 3 81103-11-9 84029
9
Dexlansoprazole Approved, Investigational Phase 4,Phase 2 138530-94-6, 103577-45-3 9578005
10
Lansoprazole Approved, Investigational Phase 4,Phase 2 103577-45-3 3883
11
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
12
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
13
Azathioprine Approved Phase 4,Phase 3 446-86-6 2265
14
Hydroxychloroquine Approved Phase 4 118-42-3 3652
15
Vincristine Approved, Investigational Phase 4,Phase 2,Phase 3 2068-78-2, 57-22-7 5978
16
Bisoprolol Approved Phase 4 66722-44-9 2405
17
Captopril Approved Phase 4 62571-86-2 44093
18
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
19
Cilazapril Approved Phase 4 88768-40-5, 92077-78-6 56330 56329
20
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
21
Enalaprilat Approved Phase 4 76420-72-9 6917719
22
Eprosartan Approved Phase 4 133040-01-4 5281037
23
Fosinopril Approved Phase 4 98048-97-6 55891
24
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
25
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
26
Losartan Approved Phase 4 114798-26-4 3961
27
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
28
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
29
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
30
Ramipril Approved Phase 4 87333-19-5 5362129
31
Spirapril Approved Phase 4 83647-97-6 5311447
32
Trandolapril Approved Phase 4 87679-37-6 5484727
33
Caffeic acid Experimental, Investigational Phase 4,Phase 3 331-39-5 1549111
34
Candesartan Experimental Phase 4 139481-59-7 2541
35 Antihypertensive Agents Phase 4,Phase 2
36 Endothelin Receptor Antagonists Phase 4,Phase 2
37 Antiemetics Phase 4,Phase 3,Phase 2
38 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Early Phase 1
39 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Early Phase 1
40 Antioxidants Phase 4,Phase 2,Phase 3,Early Phase 1
41 Autonomic Agents Phase 4,Phase 3,Phase 2
42 BB 1101 Phase 4,Phase 2,Phase 3
43 Dexamethasone acetate Phase 4,Phase 2,Phase 3 1177-87-3
44 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
45 glucocorticoids Phase 4,Phase 3,Phase 2,Early Phase 1
46 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
47 Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
48 Hormones Phase 4,Phase 3,Phase 2,Early Phase 1
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
50 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 334)

# Name Status NCT ID Phase Drugs
1 The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis Unknown status NCT02480335 Phase 4 bosentan
2 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
3 Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research(VOYAGER)Study Completed NCT00460213 Phase 4 Valsartan 80mg daily;Valsartan 160mg daily
4 PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs Completed NCT02249897 Phase 4 CHOLESTYRAMINE
5 The Study of Different Dose Rituximab in the Treatment of ITP Completed NCT03258866 Phase 4 Rituximab;Rituximab
6 A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT01390649 Phase 4
7 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
8 A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
9 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
10 Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
11 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
12 NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients Recruiting NCT02817360 Phase 4 RAS-antagonist and beta-blocker up-to maximal dosages
13 The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
14 Immunomodulation With Romiplostim in Young Adults With ITP Recruiting NCT02760251 Phase 4 romiplostim
15 Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment Active, not recruiting NCT02614898 Phase 4
16 Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS Active, not recruiting NCT02574403 Phase 4 eculizumab
17 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Not yet recruiting NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
18 Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura Not yet recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
19 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP) Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
20 Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura Withdrawn NCT01754545 Phase 4 Octaplas infusion and placebo (group 1);Octaplas infusion and placebo (group 2)
21 A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy Unknown status NCT02391272 Phase 3 rhTPO
22 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy Unknown status NCT02270801 Phase 3 rhTPO
23 Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
24 Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP Unknown status NCT01805648 Phase 3 rhTPO
25 The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP) Unknown status NCT00909077 Phase 3 Dexamethasone;Dexamethasone and Rituximab
26 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Completed NCT01295736 Phase 3 Sildenafil;placebo
27 Effects of Saxagliptin on Endothelial Function Completed NCT01319357 Phase 3 Saxagliptin;Placebo
28 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Completed NCT00406393 Phase 3 Tacrolimus;Methotrexate;Sirolimus
29 Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP) Completed NCT02868099 Phase 3 Romiplostim;Placebo
30 Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone Completed NCT02914054 Phase 2, Phase 3 High dose Dexamethasone pulses;Prednisone
31 Caffeic Acid Tablets as a Second-line Therapy for ITP Completed NCT02351622 Phase 3 Caffeic acid;Dexamethasone;Placebo
32 Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura Completed NCT02553317 Phase 3
33 An Investigation of rhTPO With Different Frequencies in the Management of ITP Completed NCT02139501 Phase 3 Recombinant Human Thrombopoietin (rhTPO)
34 Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia Completed NCT02334813 Phase 3 Prednisone;Dexamethasone
35 An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia Completed NCT02063789 Phase 3 Human immunoglobulin intravenous
36 A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT02201290 Phase 3 Eltrombopag Tablets;Eltrombopag PfOS
37 A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT02076412 Phase 3 Fostamatinib Disodium 100mg;Placebo;Fostamatinib Disodium 150mg
38 A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT02076399 Phase 3 Fostamatinib Disodium 100mg;Placebo;Fostamatinib Disodium 150mg
39 rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP Completed NCT01734044 Phase 3 recombinant human thrombopoietin (rhTPO); dexamethasone;Dexamethasone
40 Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients Completed NCT01730352 Phase 2, Phase 3 H. pylori triple therapy
41 Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) Completed NCT01438840 Phase 3 Avatrombopag;Placebo;Standard of care
42 Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia Completed NCT01349790 Phase 3 NewGam
43 rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP Completed NCT01525836 Phase 3 rituximab; recombinant human thrombopoietin (rhTPO);Rituximab
44 Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. Completed NCT01520909 Phase 3 Eltrombopag;Placebo
45 Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) Completed NCT01506414 Phase 3 rhTPO in combination with Rituximab
46 Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients Completed NCT01444417 Phase 3 Romiplostim;Placebo
47 Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) Completed NCT01410916 Phase 2, Phase 3 Eculizumab (Soliris®)
48 A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura Completed NCT01071954 Phase 3
49 Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Completed NCT00828750 Phase 3 Eltrombopag oral tablets
50 Study of Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP Completed NCT00774202 Phase 2, Phase 3 Rituxan and Cyclophosphamide, Vincristine and Prednisone;Higher Dose of Rituximab

Search NIH Clinical Center for Capillary Disease

Genetic Tests for Capillary Disease

Anatomical Context for Capillary Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Capillary Disease:

18
The Capillaries

MalaCards organs/tissues related to Capillary Disease:

38
Endothelial, Bone, Bone Marrow, Testes, B Cells, T Cells, Kidney

Publications for Capillary Disease

Articles related to Capillary Disease:

# Title Authors Year
1
Growth hormone, sorbitol, and diabetic capillary disease. ( 4100908 )
1971
2
Growth hormone, sorbitol, and diabetic capillary disease. ( 4102056 )
1971

Variations for Capillary Disease

Expression for Capillary Disease

Search GEO for disease gene expression data for Capillary Disease.

Pathways for Capillary Disease

GO Terms for Capillary Disease

Cellular components related to Capillary Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.02 ALB ATP4A CSF2 IL2 SERPING1

Biological processes related to Capillary Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 8.62 ATP12A ATP4A

Molecular functions related to Capillary Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
2 hydrogen:potassium-exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Capillary Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....